Top Page
Immutep Ltd
(Sydney:IMM)
Immutep Ltd (IMM) vs. iShares MSCI Australia ETF (EWA)
Immutep Ltd Business Overview & Revenue Model
Immutep Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.04M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -56.37M | -56.37M | -37.70M | 1.44M | -1.89M | 1.79M |
| EBITDA | -62.88M | -62.88M | -44.54M | -42.88M | -31.87M | -20.72M |
| Net Income | -61.43M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 156.98M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 129.69M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 1.63M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 13.35M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 143.64M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -62.10M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -62.05M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | -38.53M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -525.12K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Ltd Technical Analysis
Immutep Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $419.50M | ― | -35.86% | ― | ― | -19.21% | |
| ― | AU$597.04M | ― | -27.89% | ― | ― | 67.26% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$309.10M | ― | -83.97% | ― | 1271.12% | 36.87% | |
| ― | AU$119.63M | ― | -42.68% | ― | ― | 63.46% | |
| ― | AU$113.90M | ― | -83.09% | ― | ― | 55.94% | |
| ― | AU$107.88M | -13.24 | -47.98% | ― | 700.00% | 26.88% |
Immutep Ltd Corporate Events
Immutep Limited has reported significant progress in its oncology programs, particularly with the TACTI-004 Phase III trial for non-small cell lung cancer (NSCLC), which is expanding across numerous clinical sites globally. The company has achieved promising results in its INSIGHT-003 trial, showing high response and disease control rates in NSCLC patients. Additionally, Immutep’s combination therapy has demonstrated a strong median overall survival in head and neck cancer patients, potentially positioning the company for further regulatory discussions and market opportunities.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced that three abstracts related to its clinical trials for the MHC Class II agonist, eftilagimod alfa, have been accepted for presentation at the European Society for Medical Oncology Congress 2025. This includes a Phase II trial in soft tissue sarcoma, a Phase I trial in non-small cell lung cancer (NSCLC), and a pivotal Phase III trial in NSCLC. These presentations at a prestigious oncology congress underscore the potential impact of Immutep’s therapies on cancer treatment, highlighting its strategic positioning in the immunotherapy field.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of July 22, 2025. This change in shareholding involves various subsidiaries of JPMorgan, including J.P. Morgan Securities Australia Limited and J.P. Morgan Securities LLC, and reflects a shift in the voting securities landscape for Immutep Ltd, potentially impacting its market dynamics and stakeholder interests.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has announced changes in the substantial holdings of its securities, with significant transactions occurring from June 2024 to July 2025 involving major financial entities such as Citicorp Nominees Pty Limited, HSBC, and Northern Trust. These transactions indicate active trading and shifts in ownership stakes, which may affect the company’s market position and investor relations.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd announced the quotation of 7,441,304 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 18, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially strengthen its market position, providing stakeholders with increased liquidity and investment opportunities.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has announced the quotation of 33,904 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of July 18, 2025. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially benefiting its stakeholders by increasing liquidity and visibility in the market.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has announced a change in the interests of its substantial holder, JPMorgan Chase & Co. and its affiliates. The voting power of JPMorgan Chase & Co. in Immutep Ltd has decreased from 6.08% to 5.05%, indicating a reduction in their shareholding. This change reflects various transactions involving securities lending and rehypothecation agreements, impacting the company’s shareholder structure and potentially influencing its market perception.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has experienced a change in the interests of its substantial holder, Regal Funds Management Pty Ltd and its associates. The notice details the current voting power and the number of ordinary shares held by the substantial holder, reflecting an increase in their voting power from 12.81% to 13.91%. This change indicates a strengthened position for Regal Funds Management in Immutep Ltd, potentially impacting the company’s governance and strategic decisions.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd presented an update at the Jefferies Global Healthcare Conference in June 2025, highlighting its ongoing business activities. The presentation emphasized the company’s commitment to leveraging immune system capabilities to address cancer and autoimmune disorders, which could enhance its market position and influence stakeholders in the biotechnology industry.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.92 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced that its EFTISARC-NEO Phase II trial, which evaluates the combination of eftilaginod alpha (efti) with radiotherapy and KEYTRUDA® in treating resectable soft tissue sarcoma, has successfully met its primary endpoint. The trial demonstrated a significant improvement in tumor hyalinization/fibrosis compared to historical data, suggesting enhanced efficacy in transforming the tumor microenvironment and addressing the high unmet need in this aggressive cancer. The results, which highlight the potential of efti in cancer treatment, are expected to be presented at a future medical meeting.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.92 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced promising results from its INSIGHT-003 trial, demonstrating a 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) patients treated with a combination of eftilagimod alpha, KEYTRUDA®, and chemotherapy. This novel combination therapy showed significant improvement in response rates across all PD-L1 expression levels compared to historical controls, particularly benefiting patients with PD-L1 TPS below 50%, who represent a high unmet need. The trial’s favorable safety profile and strong efficacy data reinforce Immutep’s confidence in establishing a new standard of care for 1L NSCLC, potentially enhancing its industry positioning and offering significant implications for stakeholders.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.92 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced promising results from its Phase IIb trial of eftilagimod alfa (efti) in combination with KEYTRUDA® for head and neck cancer patients with PD-L1 CPS <1. The trial demonstrated a median overall survival of 17.6 months, significantly surpassing current standard treatments. This combination therapy addresses a high unmet need for patients with no available chemotherapy-free options, showing potential for regulatory approval discussions with the FDA. The safety profile remains favorable, and the company plans to continue data analysis and regulatory discussions.